Publisher
Springer Science and Business Media LLC
Reference17 articles.
1. Jin M, et al. Ramdomized 3-armed phase III study of S-1 monotherapy versus S-1/CDDP (SP) versus 5-FU/CDDP (FP) in patients (pts) with advanced gastric cancer (AGC): SC-101 study. J Clin Oncol, 26(May 20 suppl): abstr 4533, 2008
2. Goh BC, et al. Inter-ethnic variability of S-1 pharmacokinetics (PK) and correlation with CYP2A6 phenotyping. J Clin Oncol, 26(May 20 suppl): abstr 2507, 2008
3. Ridwelski K, et al. Docetaxel-cisplatin (DC) versus 5-fluorouracil-leucovorin-cisplatin (FLC) as first-line treatment for locally advanced or metastatic gastric cancer: preliminary results of a phase III study. J Clin Oncol, 26(May 20 suppl): abstr 4512, 2008
4. Rougier P, Oba K. On behalf of the Global Adv./Adj. Stomach Tumor Research Through International Collaboration (GASTRIC). J Clin Oncol, 26(May 20 suppl): abstr 4563, 2008
5. Han S, Park SR, Lee K, et al. Phase II study and biomarker analysis of cetuximab in combination with oxaliplatin, 5-fluorouracil, leucovorin as first-line treatment in patients with recurrent or metastatic gastric cancer. J Clin Oncol, 26(May 20 suppl): abstr 4549, 2008